Denali Therapeutics (DNLI) Analyst & Key Data

Analyst Consensus

Buy15 analysts

Buy

Updated Sep 12, 2026

Total Analysts15

Buy

19

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$21.09

Median Target+57.42%

$33.20

Potential upside vs current price

DCF Value-95.47%

$0.95

Potential downside vs current price

Current Stock Price

$21.09

Median Target+57.42%

$33.20

Potential upside vs current price

DCF Value-95.47%

$0.95

Potential downside vs current price

Analyst Consensus

Buy15 analysts

Buy

Updated Sep 12, 2026

Total Analysts15

Buy

19

Ratings

Updated Sep 12, 2026

Overall Rating

C

DCF Score3.0 / 5

Debt / Equity Score4.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$21.09

Median Target+57.42%

$33.20

Potential upside vs current price

DCF Value-95.47%

$0.95

Potential downside vs current price

Current Stock Price

$21.09

Median Target+57.42%

$33.20

Potential upside vs current price

DCF Value-95.47%

$0.95

Potential downside vs current price

Denali Therapeutics Inc.